Tempus Launches Prospective “Priority” Research Study and Increases Support for Oncology Research Initiatives Despite Pandemic Challenges

NEXT STORY
Junshi Biosciences and Merck Announce Collaboration to Explore Promising New COMBINATION Treatment for Head and Neck Cancer Patients in China
PREV STORY
Ehave, Inc. Adds Adviser For Clinical Trials For Its Cognitive And Psychedelic Opportunities To Medical Advisory Board
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Biohit GastroPanel® accurately predicted the progression of atrophic gastritis and its transition to gastric cancer in a European multicenter trial

Biohit Oyj press release 05.09.2018 klo 10.10 local time (EEST) A Dutch research group ...

author_avatar
NASDAQ Market News

VIFOR PHARMA GROUP REPORTS STRONG H1 2018 RESULTS, RAISES FULL-YEAR GUIDANCE

Strong financial performance in H1 2018 Three medium-term strategic growth drivers fully on track ...

author_avatar
NASDAQ Market News

Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT

NOVATO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced ...

author_avatar
NASDAQ Market News